Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.48 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345603 | 1.00 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL30345490 | 1.00 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL23744759 | 1.00 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL19617845 | 1.00 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL23744366 | 0.89 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL23744375 | 0.89 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL30345641 | 0.89 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL30345565 | 0.89 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL19617634 | 0.86 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL19617607 | 0.86 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | NPC1 1236/4885RAB9A 3190/4885SMN1; SMN2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.